Work

A phase I trial of the IGF-1R antibody IMC-A12 in combination with temsirolimus in patients with metastatic breast cancer.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.534

Authors: Gini F. Fleming, VeraJean Suman, Matthew P. Goetz, Paul Haluska, Timothy Jerome Moynihan, Rita Nanda, Olufunmilayo I. Olopade, Timothy J. Pluard, Charles Erlichman, Helen X. Chen, Zhanfang Guo, Matthew James Ellis, Cynthia X. Ma

Institutions: University of Chicago Medical Center, Mayo Clinic, University of Chicago, Washington University in St. Louis, National Cancer Institute, Washington University Medical Center, Alvin J. Siteman Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2604587333

Cites:

Cited by:

Related to: 10